Life Sciences

  • June 25, 2026

    Novo Nordisk Gets 401(k) Investment Suit Narrowed

    A New Jersey federal judge dismissed allegations accusing Novo Nordisk of unlawfully keeping underperforming investment options in its employee 401(k) plan, handing the pharmaceutical company a partial win by concluding workers hadn't identified comparable funds that performed significantly better.

  • June 25, 2026

    No Immunity In Idaho THC Child Abuse Registry Suit

    An Idaho federal judge won't throw out a class action alleging Idaho violates constitutional rights by placing women on the state's Child Protection Central Registry for using THC during pregnancy, finding the director of the state's Department of Health and Welfare doesn't have immunity against the claims.

  • June 25, 2026

    Sidley Grows In Calif. With Life Sciences, Emerging Cos. Hires

    Sidley Austin LLP announced three partner hires in California, which the firm said will enhance its capabilities in the life sciences and emerging companies and venture capital practices.

  • June 25, 2026

    4th Circ. Says Supply Co.'s Foreign Member Kills Diversity

    The Fourth Circuit on Thursday declined to reinstate a medical supply company's contract dispute against a U.K. corporation over COVID-19 test kits, after finding that the lack of a U.S. citizen on the supply company's side destroys the court's diversity jurisdiction to hear the case.  

  • June 25, 2026

    2 Firms Lead Merck's $11.3B Bio-Techne Life Sciences Deal

    Germany's Merck has agreed to acquire Bio-Techne Corp. in an all-cash deal valuing the U.S.-based life sciences tools company at about $11.3 billion, including debt, the companies said Thursday.

  • June 25, 2026

    Monsanto Wins High Court Fight Over Roundup Cancer Warnings

    The U.S. Supreme Court on Thursday handed Monsanto a win in its long-running litigation battle over the labeling of alleged cancer risks of its bestselling weedkiller Roundup, clearing the path for a $7.25 billion settlement to end thousands of suits facing the Bayer AG unit by finding that the state law claims underlying a $1.25 million jury verdict are barred.

  • June 24, 2026

    NY Judge Halts DOJ Bid For Trans Youth Medical Records

    A New York federal judge Wednesday barred the U.S. Department of Justice from seeking medical records of transgender patients who received gender-affirming care as minors in the wake of a grand jury subpoena to NYU Langone Health System, saying the government's investigation doesn't outweigh the patients' privacy interests.

  • June 24, 2026

    Wholesalers Say Novo Can't Duck GLP-1 Antitrust Suits

    Drug buyers want a New York federal judge to preserve proposed class claims accusing Novo Nordisk of paying Teva to delay generic competition with its Victoza GLP-1 drug, arguing that whatever the underlying deal was, no generic version materialized when it could have.  

  • June 24, 2026

    Florida AG Opens Probe Over CVS' Ownership Of Caremark

    Florida state enforcers are investigating CVS Corp. over concerns that its ownership of the pharmacy benefits manager Caremark allows it to steer patients to its own retail pharmacies while taking steps to hinder independent rivals.

  • June 24, 2026

    Pfizer Defeats Generic Drug Claims From State AGs

    A Connecticut federal court tossed the claims against Pfizer Inc. in one of three cases by state enforcers accusing dozens of generic-drug makers of price-fixing, finding Pfizer was not responsible for the alleged price increases on several drugs.

  • June 24, 2026

    Gene Therapy Co. Sangamo Gets Initial OK For $30M DIP

    A Delaware bankruptcy judge on Wednesday granted interim approval of a $30 million Chapter 11 financing package for biotechnology company Sangamo Therapeutics Inc., funds that the debtor will use to support a sale process for its assets.

  • June 23, 2026

    Texas Woman Says ERs Violated EMTALA Amid Miscarriage

    A Texas woman urged the U.S. Centers for Medicare & Medicaid Services to investigate two providers over their alleged violations of the Emergency Medical Treatment and Labor Act, or EMTALA, when she sought treatment for a miscarriage, arguing her case "is not an isolated incident."

  • June 23, 2026

    FTC Tells 4th Circ. Court Got It Wrong In J&J Stelara Case

    The Federal Trade Commission has told the Fourth Circuit that a Virginia federal court messed up when it ruled in an antitrust suit against Johnson & Johnson that the company bringing the suit needed to show specific intent in order to prop up a monopolization claim over the immunosuppressive drug Stelara.

  • June 23, 2026

    No Slowdown: A Midyear Look At FDA Ad Enforcement

    An FDA drug ad enforcement surge that began last year continued in the first half of 2026. Experts say the agency is looking hard at the overall impression an ad makes, including in broad emotional appeals to consumers.

  • June 23, 2026

    Stryker Says Data Breach Suit Built On Speculation

    Michigan-based medical technology company Stryker Corp. has asked a federal judge to toss a proposed class action over a March cyberattack, arguing the former and current employees suing the company cannot show their personal information was accessed or that they suffered any injury tied to the incident.

  • June 23, 2026

    Green Group Wants Records Behind Trump's Weed Killer Order

    An environmental organization on Monday sued the U.S. Department of Agriculture in D.C. federal court, seeking records behind President Donald Trump's executive order to hike the production of glyphosate, the active ingredient in the weed killer Roundup, an allegedly carcinogenic pesticide at the center of an imminent U.S. Supreme Court decision.

  • June 23, 2026

    BioNTech Accused Of Firing Nurse Over Drug Trial Concerns

    A former senior clinical trial manager at BioNTech US Inc. told a North Carolina federal court Monday that she was wrongfully fired after complaining to higher-ups about an "epidemic of safety issues and protocol deviations" in clinical trials.

  • June 23, 2026

    Feds Tout AI's Role In $6.5B Healthcare Fraud Crackdown

    Federal authorities said Tuesday that artificial intelligence and sophisticated data analysis helped them detect and prosecute healthcare fraud as part of a national crackdown that resulted in charges against 455 defendants.

  • June 23, 2026

    Fed. Circ. Backs Pfizer Win In Paxlovid Patent Dispute

    The Federal Circuit on Tuesday refused to revive a patent that Pfizer was accused of infringing through its blockbuster Paxlovid COVID-19 treatment, rejecting the patent owner's arguments over what it said was a typo in a patent document.

  • June 23, 2026

    Gene Therapy Developer Sangamo Hits Ch. 11 With Sale Plans

    Sangamo Therapeutics Inc. filed for bankruptcy protection in Delaware on Tuesday with offers to sell parts of its genetic therapy development programs to Eli Lilly and Co. and Astellas Pharma Inc.

  • June 22, 2026

    Can Unread Emails Trigger Arbitration? 9th Circ. Airs Doubts

    Medical supplies giant Thermo Fisher Scientific pressed a Ninth Circuit panel Monday to agree that the company's repeated emails about litigation waivers should send an ex-employee's proposed class action to arbitration, but the judges repeatedly questioned why no one simply asked if the worker saw the emails.

  • June 22, 2026

    Cassava Investors Ink $31M Drug Suit Deal Alongside Appeal

    Cassava Sciences investors have asked a Texas federal judge to preliminarily approve a $31 million settlement that ends their claims the pharmaceutical company inflated its stock prices with misleading information about its Alzheimer's drug research, a deal that could be upended if the court's class certification order is reversed on appeal.

  • June 22, 2026

    Zymergen Investors Get First OK For $125M Settlement

    Former executives, underwriters and large investors of now-defunct biotechnology company Zymergen received initial approval on Monday of a $125 million deal to end claims that they misled shareholders ahead of the company's initial public offering by approving misstatements about Zymergen's commercial product pipeline.

  • June 22, 2026

    FTC Requires Fix For Aurobindo's $250M Lannett Deal

    The Federal Trade Commission is allowing Aurobindo Pharma Ltd. to move ahead with its planned $250 million acquisition of Lannett Co. Inc., after the pharmaceutical company agreed to unload four generic drug products to prevent potential overlaps.

  • June 22, 2026

    No Trial For Splenda Maker, Scientist In Defamation Suit

    Splenda maker TC Heartland LLC and the scientist whom it accused of defamation were sent packing from North Carolina federal court Monday, after a judge found neither had offered evidence to overcome the other's First Amendment right to talk about scientific research.

Expert Analysis

  • Virginia's Cannabis Retail Veto Leaves Industry In Legal Limbo

    Author Photo

    Virginia Gov. Abigail Spanberger's recent veto of legislation that would have established a regulated retail cannabis framework halts momentum built by the General Assembly, but it also sends important signals about what a future regulatory framework must address to survive, says Charles Slemp at Cozen.

  • Checking For AI Errors Is Now A Two-Way Street

    Author Photo

    A handful of recent federal and state cases demonstrate the importance of checking for errors generated by artificial intelligence not only in your own court submissions, but also your opponent's, as well as when catching opposing counsel's AI mistakes could result in an award for attorney fees, says Tamara Barago at Hollingsworth.

  • Series

    The Biz Court Digest: Shoring Up Corporate Law In Maryland

    Author Photo

    Launched more than 20 years ago to improve complex corporate adjudication, Maryland's Business and Technology Case Management Program has been a solid success in some areas, but there always is room for improvement, says Bill Krulak at Miles & Stockbridge.

  • State Enviro Agencies Give Cosmetics Regulation A Makeover

    Author Photo

    As state oversight of cosmetics rapidly expands, the new statutes and regulations governing these products are being implemented by environmental agencies rather than consumer product regulators, requiring manufacturers, distributors and retailers to reevaluate their supply chains and procedures, say attorneys at Baker Botts.

  • FDA's Chemical Review Process Heats Up Food Industry Risk

    Author Photo

    The U.S. Food and Drug Administration's newly announced process for postmarket assessment of food additives signals a significant shift away from historically limited oversight, introducing both strategic opportunities and material risks for food manufacturers, ingredient suppliers and others in the food supply chain, say attorneys at Morgan Lewis.

  • Series

    Competing At Poker Makes Me A Better Lawyer

    Author Photo

    Playing poker in male-dominated rooms taught me to treat skepticism as background noise when my opponents seem to underestimate me, to apply pressure when it matters and to adapt without losing strategic discipline — skills that are all indispensable in restructuring and insolvency matters, says Alexis Gambale at Pashman Stein.

  • Why IPR Slowdown Has Not Led To More Patent Litigation

    Author Photo

    Despite sustained strength in patent application filings and a decline in inter partes review and post-grant review, 2026 has not seen the anticipated surge in patent litigation in district courts and at the U.S. International Trade Commission, potentially due to four reasons, say attorneys at Sterne Kessler.

  • 5 Things Associates Must Ask About Their Firm's Merger Plan

    Author Photo

    The associates who navigate law firm mergers best ask the right questions early, such as inquiring about partners' plans, to assess how the merger could affect their workflow and career path, says Jackie Bokser-LeFebvre at Major Lindsey.

  • Brain Computer Interfaces Boot Up Multipronged Legal Issues

    Author Photo

    As neurotechnology companies begin to conduct human clinical trials for brain computer interfaces, attorneys should prepare for legal ramifications across a broad range of practice areas, including intellectual property, privacy and product liability, say attorneys at ArentFox Schiff.

  • Turning To The Courts When PBM Reform Falls Short

    Author Photo

    The effectiveness of state laws intended to regulate pharmacy benefit managers remains uncertain, but litigation — utilizing tried-and-true theories like breach of contract and fair dealing — offers another mechanism through which stakeholders may seek relief from PBMs, say attorneys at Reed Smith.

  • 2 'Rocket Dockets' And The Rules That Propel Them

    Author Photo

    The fastest civil trial courts in the country are currently in the Eastern District of Virginia and the Southern District of Florida, and their chief judges provide insights into the court rules that keep them ahead, says Robert Tata at Hunton.

  • Calif. Ruling Lowers Bar For Health Data Breach Claims

    Author Photo

    The California Supreme Court's ruling in J.M. v. Illuminate Education offers protection for non-healthcare companies that maintain health-related data but also adopts a new and more plaintiff-favorable standard for breach of confidentiality that companies maintaining any health-related data should address, say attorneys at Cooley.

  • Teva Ruling Offers Patentees New Support For Genus Claims

    Author Photo

    The Federal Circuit's recent decision in Teva v. Eli Lilly, finding that the Teva patents at issue are not invalid, offers an interesting counterexample against the recent trend of courts invalidating patents claiming a broad, functionally defined class of compounds, say attorneys at Cooley.

  • Your Next Litigation Hold Should Cover AI Chat Logs

    Author Photo

    The Delaware Chancery Court’s recent decision in Fortis Advisors v. Krafton to treat a CEO’s artificial intelligence chats as substantive evidence is being read as a discovery warning to litigators, but there is a second duty-to-preserve lesson that is especially pertinent to in-house counsel, say attorneys at Faegre Drinker.

  • Opinion

    High Court's Abortion Pill Stay Reinforces Appellate Principles

    Author Photo

    The U.S. Supreme Court's recent order in Danco Laboratories v. Louisiana, staying a Fifth Circuit ruling that reinstated an in-person requirement for dispensing the abortion medicine mifepristone, should be seen not as a definitive ruling on reproductive rights, but as an affirmation of a more disciplined jurisdictional reality, says Daniel Nardo at Nardo & Associates.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.